Innovative Treatment Approaches in the Acute Intermittent Porphyria Market
Author : ajay abc | Published On : 20 Jan 2025
Acute intermittent porphyria (AIP) is a rare inherited metabolic disorder characterized by a disordered function in the heme biosynthesis pathway that leads to excessive accumulation of porphyrins and porphyrin precursors in the liver and other tissues. The main symptoms of AIP include severe abdominal pain, nausea, and neurological complications. AIP needs to be diagnosed promptly and adequately managed as delayed treatment can lead to life-threatening complications.
Conventionally, medications like heme arginate are used to inhibit aminolevulinic acid synthase enzyme and thereby reducing porphyrin production. Alternatively, hematin infusion therapy is also effective in treating AIP attacks. The rising awareness regarding hereditary disorders and improving diagnostic capabilities are helping identify more Acute Intermittent Porphyria Market cases.
The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031.
Key Takeaways
Key players operating in the Acute Intermittent Porphyria are Dahaner, Recordati Rare Diseases, and Orphalan.
The growing incidences of genetic disorders and rising efficacy of treatment options are fueling the demand for Acute Intermittent Porphyria therapeutics. As per some estimates, around 1 in 10,000 individuals globally suffer from AIP.
Technological advancements are enabling development of novel treatment modalities for AIP like gene therapy and stem cell transplants that can potentially cure the disease by correcting the genetic defects causing AIP.
Market Trends
The rising awareness about genetic counseling and carrier screening is enabling identification of family members with trait for AIP, who can then be monitored for development of symptoms. This is anticipated to emerge as a key trend.
Novel drug development is another trend gaining traction in the Acute Intermittent Porphyria market. Companies are engaged in R&D of advanced therapies targeting the underlying defect to achieve cure.
Market Opportunities
Undiagnosed population in developing countries present significant opportunities for market players to expand access to diagnostics and treatments for AIP.
Combination therapies amalgamating gene therapy and conventional medications hold promise for more efficacious AIP management in future. This presents lucrative opportunities.
Impact of COVID-19 on Acute Intermittent Porphyria Market Growth
The COVID-19 pandemic has significantly impacted the growth of the acute intermittent porphyria market. During the initial months of the pandemic, lockdowns and movement restrictions caused major disruptions in the supply chain and production of drugs. This led to a shortage of acute intermittent porphyria drugs in the market. The closing down of manufacturing units and non-availability of raw materials hampered the timely delivery of drugs to patients. Outpatient visits also reduced significantly as patients avoided visiting hospitals for treatment due to the fear of contracting infection. This resulted in delayed and missed diagnosis and treatment of acute intermittent porphyria attacks. With the ease of lockdowns later, manufacturing and supplies have resumed. However, the demand is still recovering to pre-COVID levels as many areas are continuing to witness intermittent lockdowns and restrictions.
North America currently holds the largest share of the acute intermittent porphyria market in terms of value. This is owing to the presence of advanced healthcare facilities, high awareness, and diagnosis rates in countries like the United States and Canada. Moreover, favorable reimbursement policies for orphan diseases also support market growth in the region. However, Asia Pacific is expected to emerge as the fastest-growing regional market during the forecast period. Factors such as rapidly developing healthcare infrastructure, rising healthcare expenditures, growing incidences of rare genetic disorders, and expanding patient pool will support the market expansion in Asia Pacific region. Countries like China, Japan, and India are likely to offer lucrative opportunities.
Europe accounts for a significant share of the global acute intermittent porphyria market. The market is primarily concentrated in Western European countries such as Germany, United Kingdom, France, Italy, and Spain owing to advanced R&D activities, availability of wide treatment options, and strong medical reimbursements. However, Central and Eastern European countries are also showing high growth potential due to increasing government focus on rare disease diagnosis and management. Geographical expansion of leading manufacturers by adopting collaborations and partnerships with regional players will further aid the market growth across European nations. Poland, Hungary, Czech Republic, among others are projected to witness fastest growth over the coming years.
Get more insights on: Acute Intermittent Porphyria Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)